N-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]methanesulfonamide;hydrochloride | 1268334-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]methanesulfonamide;hydrochloride
• CAS: 1268334-26-4
• 化学式: C25H30ClN3O6S
• 分子量: 536.0
• InChiKey: RGKLEUHEOPNTER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.46
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US10028948B2

  公开（公告）日：2018-07-24

  The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of autism spectrum disorder.

  本发明要求一种铬酮衍生物以及至少包含上述衍生物的药物组合物和组合物，该衍生物是一种多巴胺D3受体拮抗剂，用于治疗自闭症谱系障碍。
• Treatment of schizophrenia
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US10842789B2

  公开（公告）日：2020-11-24

  The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.

  本发明涉及一种治疗有需要的受试者的精神分裂症的方法，该方法包括向受试者施用治疗有效量的选择性D3拮抗剂，其中所述受试者具有PANSS中以下核心阴性症状中的至少一种阴性症状（NS）：情感迟钝（N1）、情感退缩（N2）、亲和力差（N3）、被动退缩（N4）和缺乏自发性（N6）；且具有中等或更高的严重程度。此外，还介绍了提高需要治疗精神分裂症的受试者的成功概率和/或治疗效果的方法。
• A CHROMONE DERIVATIVE AS A DOPAMINE D3 RECEPTOR ANTAGONIST FOR ITS USE FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
  申请人：Pierre Fabre Médicament

  公开号：EP3079688A1

  公开（公告）日：2016-10-19
• A CHROMONE DERIVATIVE AS A DOPAMINE D3 RECEPTOR ANTAGONIST FOR ITS USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER
  申请人：Pierre Fabre Médicament

  公开号：EP3079688B1

  公开（公告）日：2017-11-22
• TREATMENT OF SCHIZOPHRENIA
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP3703695B1

  公开（公告）日：2022-12-21